Just one day after CEO Stéphane Bancel’s sudden announcement of a 10% workforce reduction, Moderna has released Q2 2025 that that fell short of analyst expectations.

Eli Lilly’s trial evaluating Mounjaro in reducing cardiovascular risk met its endpoint, though missed analyst expectations.